

AF

JW 1632

**STATEMENT UNDER 37 CFR 1.97(e) ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

Docket No.
25429/5

In Re Application Of: Isacson et al.

| Application No. | Filing Date | Examiner | Customer No. | Group Art Unit | Confirmation No. |
|-----------------|---------------|-----------------|--------------|----------------|------------------|
| 09/917,126 | July 27, 2001 | Anne Marie Falk | 21710 | 1632 | 3321 |

Invention: **CELL IMPLANTATION THERAPY FOR NEUROLOGICAL DISEASES OR DISORDERS**



COMMISSIONER FOR PATENTS:

This is a statement under the provisions of 37 CFR 1.97(e) in the above-identified application.

Check applicable statement herebelow:

Statement Under 37 CFR 1.97(e)(1)

Each item of information contained in the accompanying Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement.

Statement Under 37 CFR 1.97(e)(2)

No item of information contained in the accompanying Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned person, after making reasonable inquiry, no item of information contained in the accompanying Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

Signature

Dated: December 22, 2005

Anthony C. Kuhlmann, Ph.D., Reg. No. 57,147

Attorney for Applicant(s)

Brown Rudnick Berlack Israels LLP

One Financial Center, Box IP

Boston, MA 02111

Tel. (617) 856-8349

Fax (617) 856-8201

Email: ip@brownrudnick.com

CC:

Certificate of Mailing by First Class Mail

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

December 22, 2005

(Date)

Signature of Person Mailing Correspondence

Seema M. Shah

Typed or Printed Name of Person Mailing Correspondence

O I P E
I A P S B
DEC 9 8 2005

Page 1 of 1

| FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT | | | ATTY DOCKET NO. | SERIAL NO. | | | |
|---|--|--------------------|-------------------------------|------------|-------|--------------|-------------------------|
| | | | 25429/5 | 09/917,126 | | | |
| | | | APPLICANT(S): Isaacson et al. | | | | |
| FILING DATE: July 27, 2001 | | | ART UNIT: 1632 | | | | |
| UNITED STATES PATENT DOCUMENTS | | | | | | | |
| EXAM. INITIAL | | DOCUMENT NUMBER | DATE | INVENTOR | CLASS | SUB CLASS | FIL. DATE IF APPR |
| | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB CLASS | TRAN Y/N |
| | | WO 00/09676 A | 02/24/2000 | PCT | C12N | 15/00 | Y |
| OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.) | | | | | | | |
| | Wagner, J. et al. Induction of a midbrain dopaminergic phenotype in Nurr1-overexpressing neural stem cells by type 1 astrocytes. <i>Nature Biotechnology</i> , 17: 653-659, 1999. | | | | | | |
| | Lindvall, O. Engineering neurons for Parkinson's disease. <i>Nature Biotechnology</i> , 17: 635-636, 1999. | | | | | | |
| | Gray J.A., et al. Prospects for the clinical application of neural transplantation with the use of conditionally immortalized neuroepithelial stem cells. <i>Phil. Trans. R. Soc. Lond B</i> , 354: 1407-1421, 1999. | | | | | | |
| | Fricker, J. Human neural stem cells on trial for Parkinson's disease. <i>Molecular Medicine Today</i> , 5(4): 144, 1999. | | | | | | |
| | Gage, F. H. Discussion point-Stem cells of the central nervous system. <i>Current Opinion in Neurobiology</i> , 8: 671-676, 1998. | | | | | | |
| | Studer, L., et al. Transplantation of expanded mesencephalic precursors leads to recovery in Parkinsonian rats. <i>Nature Neuroscience</i> , 1(4): 290-295, 1998. | | | | | | |
| | Valarce, I., et al. The mouse homeodomain protein Phox2 regulates Ncam promoter activity in concert with Cux/CDP and is a putative determinant of neurotransmitter phenotype. <i>Development</i> , 119: 881-895, 1993. | | | | | | |
| | Lee, S-H., et al. Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells. <i>Nature Biotechnology</i> , 18: 675-679, 2000. | | | | | | |
| | Ben-Hur, T., et al. Transplantation of Human Embryonic Stem Cell-Derived Neural Progenitors Improves Behavioral Deficit in Parkinsonian Rats. <i>Stem Cells</i> , 22(7): 1248-1255, 2004. | | | | | | |
| Examiner: | | | | Date: | | | |
| | | | | | | | |